Core Concepts
The European Commission has approved danicopan, a first-in-class complement factor D inhibitor, as an add-on therapy for adult patients with paroxysmal nocturnal hemoglobinuria (PNH) and continuing clinically significant extravascular hemolysis despite treatment with standard complement blockade.
Abstract
The content discusses the approval of danicopan, a novel oral complement inhibitor, by the European Commission for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). PNH is a rare, chronic, and progressive disease caused by a genetic mutation that leads to the expansion of abnormal blood cells deficient in glycosylphosphatidylinositol-linked proteins. This results in complement activation, intravascular hemolysis, and various complications such as thrombosis, infections, and bone marrow failure.
The standard treatment for PNH is complement blockade using anti-C5 monoclonal antibodies like ravulizumab or eculizumab. However, 10-20% of treated patients still experience clinically significant extravascular hemolysis and residual hemolytic anemia. Danicopan, a selective inhibitor of complement factor D, has been approved as an add-on therapy to the standard complement blockade to address this unmet need.
The approval is based on the results of the ongoing phase 3 ALPHA trial, which showed that the addition of danicopan to ravulizumab or eculizumab resulted in a statistically significant increase in mean hemoglobin levels at 12 weeks, along with reduced fatigue, anemia, and transfusion requirements. Danicopan was generally well-tolerated, with no serious adverse events reported.
Stats
The addition of danicopan to ravulizumab or eculizumab resulted in a statistically significant increase in mean hemoglobin level of 2.94 g/dL at 12 weeks, compared to 0.50 g/dL with placebo.
Despite best supportive care, the 5-year and 10-year mortality rates for PNH are approximately 35% and 50%, respectively.
Quotes
"Danicopan is an oral selective inhibitor of factor D, a complement system protein that plays a key role in the amplification of the complement system response in PNH."
"The drug was generally well tolerated, with no serious adverse events reported."